Want to see ACET full AI Analyst Report?
ACET Stock Chart & Stats
$9.00
-$0.63(-7.48%)
At close: 4:00 PM EDT
$9.00
-$0.63(-7.48%)
Day’s Range― - ―
52-Week Range$4.57 - $16.96
Previous Close$7.79
Volume71.21K
Average Volume (3M)287.19K
Market Cap
$42.78M
Enterprise Value-$12.49M
Total Cash (Recent Filing)$118.19M
Total Debt (Recent Filing)$12.85M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Nov 11, 2026EPS Estimate
-1.58Next Dividend Ex-DateN/A
Dividend Yield<0.01%
Share Statistics
EPS (TTM)-11.45
Shares Outstanding9,361,490
10 Day Avg. Volume235,457
30 Day Avg. Volume287,192
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap-0.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.31
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$25.00Price Target Upside177.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-6.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Prula-cel Clinical ProgressPrula-cel has produced meaningful early autoimmune-disease results alongside a generally favorable safety profile, including no dose-limiting toxicities or severe CRS. Planned pivotal lupus nephritis development creates a potentially important path toward a differentiated, one-time treatment.
Diversified Clinical PipelineThe pipeline spans autoimmune disease, blood cancers and solid tumors, reducing dependence on a single indication if programs advance successfully. IND clearance for ADI-212 and additional planned studies provide multiple opportunities for future clinical validation and platform expansion.
Conservative LeverageLow leverage limits the immediate burden of debt service and preserves more financial flexibility than a highly indebted balance sheet would provide. This supports continued investment in clinical programs and leaves financing choices less constrained by existing debt obligations.
Bears Say
No Meaningful Commercial RevenueThe absence of meaningful product revenue means Adicet has not yet demonstrated a recurring commercial engine to fund operations. Until a therapy is approved and launched, the company remains dependent on clinical progress and external capital rather than internally generated business cash flow.
Persistent Cash BurnHigh and continuing cash consumption creates a durable funding requirement while multiple therapies remain in development. External financing may be needed to sustain trials and operations, making future progress sensitive to capital availability and potentially dilutive funding decisions.
Shrinking Equity Base And LossesThe shrinking equity base alongside recurring losses signals substantial value erosion despite modest loss narrowing. Continued negative returns and development spending can weaken financial resilience over time, limiting the resources available to absorb delays or expand the pipeline.
Adicet Bio News
ACET FAQ
What was Adicet Bio’s price range in the past 12 months?
Adicet Bio lowest stock price was $4.57 and its highest was $16.96 in the past 12 months.
What is Adicet Bio’s market cap?
Adicet Bio’s market cap is $42.78M.
When is Adicet Bio’s upcoming earnings report date?
Adicet Bio’s upcoming earnings report date is Nov 11, 2026 which is in 23 days.
How were Adicet Bio’s earnings last quarter?
Adicet Bio released its earnings results on Aug 05, 2026. The company reported -$1.99 earnings per share for the quarter, missing the consensus estimate of -$1.692 by -$0.298.
Is Adicet Bio overvalued?
According to Wall Street analysts Adicet Bio’s price is currently Undervalued.
Does Adicet Bio pay dividends?
Adicet Bio pays a Quarterly dividend of $0.01 which represents an annual dividend yield of <0.01%. See more information on Adicet Bio dividends here
What is Adicet Bio’s EPS estimate?
Adicet Bio’s EPS estimate is -1.58.
How many shares outstanding does Adicet Bio have?
Adicet Bio has 9,361,490 shares outstanding.
What happened to Adicet Bio’s price movement after its last earnings report?
Adicet Bio reported an EPS of -$1.99 in its last earnings report, missing expectations of -$1.692. Following the earnings report the stock price went down -13.428%.
Which hedge fund is a major shareholder of Adicet Bio?
Currently, no hedge funds are holding shares in ACET
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adicet Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.00 (177.78% Upside)
$25.00 (177.78% Upside)
Blogger Sentiment
Bullish
ACET Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 563.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.53%
12-Months-Change
Fundamentals
Return on Equity
-74.90%
Trailing 12-Months
Asset Growth
-9.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Adicet Bio
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
ACET Stock 12 Month Forecast
Average Price Target
$25.00
▲(177.78% Upside)
Technical Analysis
Sutro Biopharma
―
PMV Pharmaceuticals
―
Gain Therapeutics
―
Immix Biopharma
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
21.99% Insiders
9.73% Mutual Funds
35.57% Other Institutional Investors
28.14% Public Companies and
Individual Investors